Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of Irinotecan Liposome Combined With Anlotinib as Second-line Regimen in Patients With Small Cell Lung Cancer

NCT06258642 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT06258642
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06258642 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of Irinotecan Liposome Combined With Anlotinib as Second-line Regimen in Patients With Small Cell Lung Cancer
Lead sponsor
Fudan University
Phase
Not applicable
Overall status
Recruiting
Start date
April 17, 2024
Completion date
December 31, 2026
Enrollment
39 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung cancer recurrent